Even at $2M+, ICER calls blue­bird's po­ten­tial gene ther­a­py for blood dis­or­der 'su­pe­ri­or' to stan­dard of care

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, a drug pric­ing watch­dog, gave a mea­sured thumbs up on Thurs­day morn­ing to blue­bird’s po­ten­tial­ly ex­pen­sive new gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.